Dopamine D2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial

Epidemiological evidence suggests that obesity may be causally associated with colorectal cancer. Dopamine and the dopaminergic reward pathway have been implicated in drug and alcohol addiction as well as obesity. Polymorphisms within the D2 dopamine receptor gene (DRD2) have been shown to be associated with colorectal cancer risk. We investigated the association between DRD2 genotype at these loci and the risk of colorectal adenoma recurrence in the Polyp Prevention Trial. Odds ratios (OR) and 95% confidence intervals (CI) for risk of adenoma recurrence were calculated using unconditional logistic regression. Individuals with any, multiple (≥2) or advanced adenoma recurrence after 4 years were compared to those without adenoma recurrence. Variation in intake of certain dietary components according to DRD2 genotype at 3 loci (rs1799732; rs6277; rs1800497) was also investigated. The DRD2 rs1799732 CT genotype was significantly associated with all adenoma recurrence (OR: 1.30; 95% CI: 1.01, 1.69). The rs1800497 TT genotype was also associated with a significantly increased risk of advanced adenoma recurrence (OR: 2.40; 95% CI: 1.11, 5.20). The rs1799732 CT and rs1800497 TT genotypes were significantly associated with adenoma recurrence in the Polyp Prevention Trial. Increased risk of adenoma recurrence as conferred by DRD2 genotypes may be related to difference in alcohol and fat intake across genotypes. Published 2008 Wiley‐Liss, Inc.

[1]  H. Ko,et al.  Specific personality traits and dopamine, serotonin genes in anxiety–depressive alcoholism among Han Chinese in Taiwan , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  E. Molinari,et al.  D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eatingrelated psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity , 2007, Eating and weight disorders : EWD.

[3]  Nilanjan Chatterjee,et al.  DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2006, Pharmacogenetics and genomics.

[4]  N. Chatterjee,et al.  Inflammatory Cytokine Gene Polymorphisms, Nonsteroidal Anti-Inflammatory Drug Use, and Risk of Adenoma Polyp Recurrence in the Polyp Prevention Trial , 2006, Cancer Epidemiology Biomarkers & Prevention.

[5]  S. Carobbio,et al.  Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion* , 2005, Journal of Biological Chemistry.

[6]  Federica Gemignani,et al.  Polymorphisms of the Dopamine Receptor Gene DRD2 and Colorectal Cancer Risk , 2005, Cancer Epidemiology Biomarkers & Prevention.

[7]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[8]  Jean Logan,et al.  Brain dopamine and obesity , 2001, The Lancet.

[9]  S. Basu,et al.  Decreased Dopamine Receptor Expression and Its Second-Messenger cAMP in Malignant Human Colon Tissue , 1999, Digestive Diseases and Sciences.

[10]  D. Collier,et al.  Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia , 1998, Schizophrenia Research.

[11]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[12]  É. Mezey,et al.  Substantial production of dopamine in the human gastrointestinal tract. , 1997, The Journal of clinical endocrinology and metabolism.

[13]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[14]  D. Comings,et al.  The D2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome , 1996, Journal of the Royal Society of Medicine.

[15]  J. Weissfeld,et al.  The polyp prevention trial II: dietary intervention program and participant baseline dietary characteristics. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  A. Schatzkin,et al.  The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  R. Klein,et al.  A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records. , 1993, The Journal of nutrition.

[18]  G. Mason,et al.  Dopamine receptors in human gastrointestinal mucosa. , 1987, Life sciences.

[19]  G Block,et al.  A data-based approach to diet questionnaire design and testing. , 1986, American journal of epidemiology.

[20]  E. Ponce,et al.  World Cancer Research Fund, American Institute for Cancer Research. Second Expert Report, Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. United Kingdom: WCRF/AICR, 2001 , 2009 .

[21]  E. Noble,et al.  Association of Seven Polymorphisms of the D2 Dopamine Receptor Gene with Brain Receptor-Binding Characteristics , 2004, Neurochemical Research.

[22]  North American Association for the Study of Obesity , 1991, International journal of obesity.